Kornimate/medical-research-clean huggingface dataset:
clinical efficacy of the neoadjuvant chemotherapy for ib2 and iia2 stage cervical cancer patients

Conditions: Uterine Cervical Neoplasm; Cervical Cancer; Uterine Cervical Cancer

Summary: in recent years, the patients with ib2 and iia2 stage cervical cancer are still treated with radiotherapy and chemotherapy based treatment, but the radiotherapy will severely damage the function of ovary, cause endocrine dyscrasia and the sexual function of vagina. so we want to study whether neoadjuvant chemotherapy without radiotherapy will achieve the same outcome compared with traditional therapy including radiotherapy. so we randomly divide ib2 and iia2 stage cervical cancer patients into two groups. the neoadjuvant chemotherapy group will receive two courses of chemotherapy basically composed of platinum, and then undergo surgery, after that, doctors will add more courses of chemotherapy according to the situations of the patients, including whether the patients have the adverse prognostic factors. the control group will undergo surgery directly, and then receive chemotherapy and radiotherapy at the same time. then we will compare the outcomes of these two groups, and analyze the therapeutic effect, the impact on survival rate and the effect on improving the living quality of patient from two groups. all the outcomes will be fed back to clinical doctors and instruct them to choose better treatment for patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis ib2 or iia2 stage cervical cancer; * age less than or equal to 65 years old; * laboratory examination results: wbc ≥ 4\*10\^9/l, neu ≥ 20\*10\^9/l, plt ≥ 80\*10\^9/l, serum bilirubin ≤ 2 multiples of the upper normal limit, aminopherase ≤ 2 multiples of the upper normal limit. bun ≤ normal limit, cr ≤ normal limit; * karnofsky score ≥ 60; * no prior treatment; * pathological diagnosis before surgery is invasive squamous cell carcinoma of cervix; * well-compliance and willing to keep in touch; * willing to participate in this study, and sign the informed consent; exclusion criteria: * participate in other drug clinical trials at the same time; * respiratory depression, airway obstruction and hypoxia; * heart diseases (cardiac function at grade ii, iii or above); * hematological diseases; * obvious dysfunction of liver and kidney (above 3 multiples of the upper normal limit); * a history of brain dysfunction; * unable to receive surgery and/or unsuitable for radiotherapy or chemotherapy; * drug abuse or a history of drug abuse; * unable or unwilling to sign informed consents; * unable or unwilling to follow the protocols;
dx-8951f in treating previously untreated patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of dx-8951f in treating patients who have previously untreated stage iiib or stage iv non-small cell lung cancer.

objectives: i. determine the antitumor activity of dx-8951f in previously untreated patients with stage iiib or iv non-small cell lung cancer. ii. evaluate the quantitative and qualitative toxic effects of this regimen in these patients. iii. evaluate the pharmacokinetics of this regimen in these patients. iv. assess the time to progression and survival status of these patients. outline: this is a multicenter study. patients receive dx-8951f iv over 30 minutes daily for 5 days. treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months for survival. projected accrual: a total of 12-37 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed unresectable, metastatic, or recurrent non-small cell lung cancer stage iiib or iv measurable disease no known brain metastases patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 12 weeks hematopoietic: absolute neutrophil count greater than 1,500/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin no greater than 1.5 mg/dl sgot or sgpt no greater than 2 times upper limit of normal (uln) (no greater than 5 times uln if liver metastases present) renal: creatinine no greater than 2.0 mg/dl cardiovascular: no active congestive heart failure other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no concurrent serious infection no other malignancy within past 5 years except nonmelanomatous skin cancer no overt psychosis, mental disability, or incompetence no life threatening illness prior concurrent therapy: biologic therapy: no concurrent biologic therapy chemotherapy: no prior chemotherapy no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: no prior radiotherapy to greater than 25% of the bone marrow no concurrent radiotherapy surgery: no concurrent surgery other: at least 28 days since prior investigational drugs no other concurrent investigational drugs during or within 28 days after final dose of study drug no concurrent drugs that induce or inhibit cyp3a enzyme

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
clinical evaluation of reusable soft contact lenses

Conditions: Myopia

Summary: the purpose of this study was to confirm the clinical performance of a novel manufacturing process for comfilcon a contact lenses in habitual wearers over a one-month period of lens wear.

this was a prospective, multiple day, double-masked (investigator and subject), randomized, bilateral re-fit parallel arm study comparing a test lens against an appropriate control lens. participants were randomized to wear the test or control lens for 30±2 days.

Eligibility criteria:
inclusion criteria: * have had a self-reported oculo-visual examination in the last year. * are at least 18 years of age and has full legal capacity to give their informed consent. * have read and understood the informed consent letter. * are willing and able to follow instructions and maintain the appointment schedule. * have a contact lens spherical prescription between -0.50 d to -6.00 d (inclusive) * are correctable to a visual acuity of 20/40 or better (in each eye) with their habitual vision correction or 20/20 best-corrected. * have spectacle cylinder of ≤ 0.75 d in both eyes. * is a habitual comfilcon a wearer and worn a comfilcon a lens for at least one month (minimum of 8 hours a day, 5 days per week) * currently employ the use of a peroxide or multipurpose solution cleaning and disinfecting regimen in one of the following brand names: * bausch and lomb biotrue multi-purpose solution * bausch and lomb biotrue hydration plus multi-purpose solution * bausch and lomb renu advanced formulation multi-purpose solution * alcon opti-free puremoist with hydraglyde multi-purpose solution * alcon opti-free replenish multi-purpose solution * alcon clear care plus hydrogen peroxide solution * acuvue revitalens multi-purpose solution * have clear corneas and no active ocular disease. * have not worn habitual lenses for at least 12 hours before the baseline/screening examination * are willing to wear the study contact lenses for at least 8 hours per day, 5 days per week exclusion criteria: * have never worn contact lenses before. * are currently wearing daily disposable contact lenses. * have any systemic disease affecting ocular health. * are using any systemic or topical medications that will affect ocular health. * have any ocular pathology or abnormality that would affect the wearing of contact lenses. * have any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars. * are aphakic. * have undergone corneal refractive surgery. * are participating in any other type of eye related clinical or research study. * require a change in lens power from more than 1 diopter as dictated by over-refraction with their habitual lens prescription.
a safety and efficacy study of bavituximab plus docetaxel in patients with advanced breast cancer

Conditions: Breast Cancer

Summary: the purpose of the study is to determine the overall response to a combination of bavituximab and docetaxel in patients with advanced breast cancer


Eligibility criteria:
inclusion criteria: * adult females over age 18 with life expectancy of at least 3 months * histologically or cytologically confirmed locally advanced or metastatic breast cancer * one and only one prior chemotherapy regimen (no prior docetaxel) * measurable disease (at least one target lesion)at least 2 cm in longest diameter (1 cm by spiral ct) * adequate hematologic, renal, and hepatic function; exclusion criteria: * known history of bleeding diathesis or coagulopathy * any current evidence of clinically significant bleeding * any history of thromboembolic events * concurrent hormone therapy * prior immunotherapy or radiotherapy to an area of measurable disease unless disease has recurred after radiotherapy

Keywords: breast cancer docetaxel chemotherapy bavituximab monoclonal antibody
review of palliative radiotherapy in the management of advanced head and neck cancer

Conditions: Head and Neck Cancer

Summary: to describe the charactersitics of patients with advanced head and neck cancer treated with palliative intent and determine outcome in terms of symptom control and toxicity


Eligibility criteria:
inclusion criteria: * squamous cell carcinoma of the head and neck, primary treatment given with palliative intent exclusion criteria: * radical treatment, palliative treatment following local recurrence, adenocarcinoma, salivary gland carcinoma or melanoma

Keywords: head and neck cancer palliation radiotherapy
inflammation in methamphetamine and stis (imsti)

Conditions: Methamphetamine-dependence; Rectal Gonorrhea; Rectal Chlamydia

Summary: this clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and hiv/sti risk behavior. this clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. the proposed trial will consist of 40 msm, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.


Eligibility criteria:
inclusion criteria: * cisgender male * 18 years of age or older * understand written and spoken english * condomless receptive anal intercourse in past 90 days * meet dsm-5 criteria for methamphetamine use disorder * positive urine toxicology screen for ma metabolites at study entry * negative rectal gc/ct screen (n=20) or positive rectal gc and/or ct screen (n=20) * able to provide written informed consent and willing/able to complete study visits. exclusion criteria: * reports current treatment for another substance use disorder * positive test for opioids, cocaine, and/or hallucinogens * treatment for gonorrhea and/or chlamydia infection in past 3 months * presence of a condition that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
efficacy of brisk walking in parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease (pd) is the second most common neuro-degenerative disease in older people. falls are common among people pd with the incidence rate up to 70% and have strong associations with the severity of the disease, balance impairment, and freezing of gait.the abnormal gait characteristics include reduction in stride length, gait speed and arm swing, and increase in cadence. gait training, balance training, aerobic training, tai chi and dance training are common types of physical rehabilitation for pd. brisk walking is a way of walking with a pace faster than normal, and it can improve dynamic balance for senior men and balance function for chronic stroke clients. brisk walking also promotes cardiopulmonary fitness and walking endurance in elderly women, healthy middle-age and older adults, active elderly men and chronic stroke clients. our previous pilot randomized controlled trial on the effects of a 6-week home-based brisk walking program indicates that it is feasible and safe for the early pd population with improved walking capacity measured by 6-minute walk distance. the positive effects could carry over to 6 weeks after treatment completion. up-to-date, the short- and long-term effects of brisk walking in improving balance and gait performance, and functional capacity in people with pd have not yet been well investigated. in order to promote their balance and functional capacity in longer term, more sustained training and better exercise adherence may be necessary.


Eligibility criteria:
inclusion criteria: * parkinson disease diagnosed by neurologist with hoehn \& yahr stage 2 or 3 * having a 30-meter walking ability exclusion criteria: * significant neurological condition (other than parkinson's disease) * musculoskeletal conditions affecting gait, balance or upper limb functions * had received deep brain stimulation surgery * cognitive impairment with montreal cognitive assessment score \<24 * present with on-off motor fluctuations.

Keywords: rehabilitation exercise postural balance
comparison of the effect of cervical mucus cleaning method applied before embryo transfer on pregnancy rates.

Conditions: Infertility

Summary: to assess the impact of cervical mucus cleansing before embryo transfer and compare two different instruments for this purpose.

all patients will be informed about the study and those who give written consent will be included in the study. women undergoing good quality embryo transfer will be assigned to one of the 3 arms of the study according to the previously determined randomization chart. the first evaluation of the patient will be made on the 12th day after embryo transfer. pregnancy status will be evaluated with serum βhcg value. if pregnancy is confirmed by serum βhcg value, fetal viability will be evaluated by ultrasound 4 weeks after transfer.

Eligibility criteria:
inclusion criteria: * 21-40 years old women, * women undergoing good quality embryo transfer, * women who are eligible for a single or double embryo transfer. exclusion criteria: * if there is a diagnosis of a uterine anomaly, * if there is a diagnosis of myoma uteri, * if there is a diagnosis of rheumatological disease, * women to be transferred other than good quality embryo, * hi̇story of previous pelvic, gynecological operation.

Keywords: cervical mucus embryo transfer pregnancy rate
follow-up of patients bound for pci after implementation of a helicopter emergency medical system

Conditions: ST-elevation Myocardial Infarction

Summary: this study compares patients bound for percutaneous coronary intervention (pci) who were transported by either ground ambulance or emergency medical helicopter. the investigators describe long-term follow-up in relation to mortality and labour affiliation.

since 2003, percutaneous coronary intervention (pci) for st-segment elevation myocardial infarction (stemi) has been the preferred therapy in denmark over fibrinolysis (thrombolysis) if performed within 120 minutes. nevertheless, centralisation of designated pci-centres may lead to systems delays as transport distance may be longer instead of just choosing thrombolysis at the nearest hospital. as every minute counts when trying to minimize the ischemic injury and size of infarction following an acute coronary event, timely transportation by helicopter may facilitate overall prognosis. as a part of a national initiative to improve prehospital care of patients with time critical illness such as myocardial infarction (mi), the first danish helicopter emergency medical system (hems) was implemented in the eastern part of denmark may 1st 2010. an initial study on 450 patients investigating short-term effects, found that hems significantly reduced time from the first electrocardiogram (ecg) diagnosis on-scene to arrival at the cardiac catheterisation laboratory (ccl) despite longer transport distances. investigators also found a lower, but insignificant 30-day mortality in hems patients, adjusted or=0.40 (95% ci=0.12-1.39, p=0.14). the aim of the present study is to investigate long-term effects of hems in relation to mortality and labour market affiliation.

Eligibility criteria:
inclusion criteria: * the investigators include all stemi patients having acute coronary angiography performed at the pci centre at copenhagen university hospital, rigshospitalet in a 40-month period from january 1st 2010 until april 30th 2013; and who were diagnosed with stemi within the geographical area covered by both hems and gems. patients with multiple contacts; only first contact is eligible. exclusion criteria: * the investigators exclude patients with cardiac arrest before hospital admission. for labour market analyses the investigators exclude patients not working full time three weeks prior to admission.
antimicrobial pastes and clinical cases of apexogenesis

Conditions: Apexification; Root Canal Therapy; Dental Trauma

Summary: the aim of this study was to perform a clinical and microbiological evaluation of teeth with incomplete apexogenesis and traumatic necrosis that were treated with a revascularization technique, evaluating the microbial reduction after the use a double antibiotic paste. furthermore, the investigation also aims to identify the presence of enterococcus faecalis and porphyromomas gingivalis within the root canal system.

this investigation is a longitudinal prospective interventional study of a series of cases. patients who sought treatment at the faculty of dentistry from june 2011 to september 2015 were selected. they should have one permanent tooth with traumatic necrosis.

Eligibility criteria:
inclusion criteria: * they should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. exclusion criteria: * patients who did use antibiotics * patients who did loss of temporary coronary sealing between treatment sessions * patients who give up the research

Keywords: anti-microbial agents apexification dental pulp endodontics root canal therapy dental trauma
early surgery for patients with asymptomatic aortic stenosis

Conditions: Aortic Valve Stenosis; Aortic Valve Surgery

Summary: many cardiologists are convinced that early surgery in asymptomatic aortic stenosis (as) saves lives. however there is currently no direct evidence for this and most recommendations from the esc/ eacts or acc/ aha in this field are supported by level-b or c evidence. therefore, the investigators designed a randomized controlled trial to demonstrate whether early surgery improves mortality and morbidity of patients with asymptomatic severe as and low operative risk.


Eligibility criteria:
inclusion criteria * adult patient, aged between 18 and 80 years (18 ≤ age ≤80) * low operative risk, defined as euroscore ii ≤ 5% * no symptom potentially attributable to as: no dyspnea, angina or syncope during exercise * no class i indication for surgery * no symptom/ fall in blood pressure during exercise test * severe as according to current echocardiography criteria: vmax \> 4.0 m/s and/ or mpg \> 40 mm hg); ava \< 1.0 cm2 (not mandatory) * preserved lv systolic function: lvef \>50% according to echocardiography ; no lv wall motion abnormality * signed informed consent exclusion criteria * moderate/ high operative risk for aortic valve replacement, defined as euroscore ii \> 5% * class-i indication for avr (esc-eacts 2012, acc/ aha 2014) or fall in blood pressure during exercise testing (class-iia) * other indication for cardiac surgery (cabg, thoracic aorta) * positive exercise test including a/ unmasking of symptoms (angina, dyspnea at low workload, dizziness or syncope) during exercise or b/ fall in systolic blood pressure during exercise below the baseline value. * patients unable to perform the exercise ecg * more than mild ar (\>grade 2/4)/ other significant valve disease lvef ≤ 50% * serum creatinine \>160 μmol/l * serious extra cardiac comorbidity/ life expectancy \<2 years * patient included in another trial with signed informed consent * patient not affiliated to social insurance * pregnancy

Keywords: aortic valve stenosis surgery
ultrasonography versus palpation for identification of the cricothyroid membrane

Conditions: Airway Obstruction

Summary: after a structured teaching program anaesthetists are educated in identifying the cricothyroid membrane with ultrasonography. thereafter their ability to do so is compared with their ability to do so with palpation. in an obese volunteer

after a structured teaching program anaesthetists are educated in identifying the cricothyroid membrane with ultrasonography. thereafter their ability to do so is compared with their ability to do so with palpation. the purpose is to advise a propriety method for preanesthetic identification. in an obese volunteer

Eligibility criteria:
inclusion criteria: * bmi \> 40 * female exclusion criteria: * age below 18

Keywords: airway obstruction
evaluation of tonabersat for dme

Conditions: Diabetic Macular Edema

Summary: this randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (cst) in eyes with center-involved diabetic macular edema (ci-dme) and good visual acuity.

the primary objective is to assess the effects of tonabersat, an orally administered connexin43 hemichannel inhibitor, on central subfield thickness (mean change) compared with placebo in eyes with ci-dme and good visual acuity at 6 months. exploratory objectives will evaluate biomarkers of kidney function for potential benefit. furthermore, this phase 2 study is being conducted to determine whether the conduct of a phase 3 trial has merit and provide information on outcome measures needed to design a phase 3 trial.

Eligibility criteria:
key inclusion criteria 1. adults with type 1 or 2 diabetes mellitus 2. at least one eye with: * best corrected e-etdrs visual acuity letter score ≥ 74 (i.e., 20/32 or better) * ophthalmoscopic evidence of center-involved dme in study eye confirmed by central subfield thickness on spectral domain oct * zeiss cirrus: ≥ 290 µm in females, ≥ 305 µm in males * heidelberg spectralis: ≥ 305 µm in females, ≥ 320 µm in males * recruitment will be monitored with a goal to have equal proportions in the following categories above the ci-dme thresholds: \<75 μm, 75 μm to \<175 μm, ≥175 μm 3. media clarity, pupillary dilation, and study participant cooperation sufficient for adequate oct key exclusion criteria * macular edema is considered to be due to a cause other than dme * major ocular surgery within prior 4 months, or anticipated after randomization * history of focal/grid laser or other ocular surgical, intravitreal, or peribulbar treatment for dr or dme within prior 1 year, and no more than 4 anti-vegf injections within prior 3 years * anticipated need to treat dme or dr during the first 6 months, or anticipated need for cataract surgery during study period * any history of vitrectomy * systemic anti-vegf or pro-vegf treatment within 12 months prior to randomization * history of chronic renal failure requiring dialysis or kidney transplant * history of moderate to severe hepatic impairment, including known liver function test (lft) values \> 3x's the upper limit of normal